[{"id":"ad48bd20-c083-465e-8b6a-3e76d93f60e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04581967","created_at":"2021-01-18T21:51:53.388Z","updated_at":"2024-07-02T16:36:40.192Z","phase":"","brief_title":"Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients","source_id_and_acronym":"NCT04581967","lead_sponsor":"Damanhour University","biomarkers":" ALDH3A1","pipe":"","alterations":" ","tags":["ALDH3A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 01/15/2021","study_completion_date":" 01/15/2021","last_update_posted":"2020-10-09"}]